Duke and Ardais Establish Biorepository for Cancer Programs
Ardais and the Duke University Medical Center this week announced a biorepository, based on Ardais’ Biospecimen Management System, to support Duke’s cancer programs.
The biorepository will encompass: institution-wide collection and archiving of samples and data; ethics-based protocols for collection, processing, archiving and dissemination; IT capabilities for processing large volumes of clinical data; and the ability to network with other cancer centers and drug developers in the future. It will provide human biomaterials and clinical data for research.
Ciphergen Sells ProteinChip Systems to Japanese Drug Discovery Proteome Project
Ciphergen Biosystems announced this week that its Japanese subsidiary has been named one of the official technology suppliers of the Japanese Drug Discovery Proteome Factory project.
Ciphergen has so far sold to the project three ProteinChip AutoBiomarker Systems and two ProteinChip interfaces for use with tandem mass spectrometry.
HapMap Project Solicits Proposals for One-Cent Genotypes
The National Institutes of Health announced Friday that it will devote $6.5 million in FY 2004 to fund another member of the International HapMap Consortium.
The newest RFA solicits research proposals for completing large-scale genotyping of at least 2.25 million SNPS in the 270 HapMap samples in less than one year — at a total cost of $.01 or less per successful genotype.
The awardee will be able to choose which SNPs to genotype, but will be expected to cooperate with other HapMap groups and to release data quickly to the HapMap Data Coordination Center.
The expiration date on the RFA is June 26 and the anticipated award date is Sept. 17.
Zeptosens Licenses Reagents from Cell Signaling Technology
Zeptosens of Witterswil, Switzerland announced this week that it has signed an agreement with Beverly, Mass.-based Cell Signaling Technology for the use of CST’s reagents in Zeptosens’ ZeptoMark protein array platform.
The reagents used will include phosphospecific antibodies to kinases and other signaling molecules, according to the companies. Financial details of the agreement were not disclosed.
Marligen Gets $100,000 from ASM Resources
Marligen Biosciences has received $100,000 from ASM Resources, ASMR said this week.
Marligen, based in Ijamsville, Md., offers products and services for gene expression analysis, genotyping, and nucleic acid purification. ASMR, based in Washington, DC, is a for-profit venture capital firm owned by the American Society for Microbiology. It supports early-stage biotechnology companies.
Mayo Establishes Genomics of Addiction Program
The Mayo Clinic announced last week that it has established a genomics of addiction program that will funded with $20 million over five years.
The program will seek first to identify human genes linked with susceptibility to alcoholism, and then to develop preventative measures for those at risk, Mayo said. The program will be called the Samuel C. Johnson Program in the Genomics of Addiction. It is named for the patriach of the SC Johnson family that owns the consumer products company, which has committed $12 million to the program. Mayo will raise the remaining $8 million.
CombiMatrix to Collect $13.6M From Direct Share Offering
Acacia Research has found buyers for a three-million share offering of common stock in its CombiMatrix life sciences unit, the Newport Beach, Calif.-based company said last week.The offering is expected to raise some $13.6 million for Acacia’s Mulkiteo, Wash., subsidiary.
The registered direct offering to a group of undisclosed institutional investors is priced at $5 a share, the company said.
SynX Shareholders, Ontario Court Ok Acquisition BY Nanogen
Nanogen of San Diego and Toronto-based SynX Pharma said this week that the Ontario Superior Court of Justice and SynX shareholders have approved Nanogen's proposed all-stock acquistion of SynX.
The transaction is valued at approximately CA$16.3 million (US$12 million) and will be based on an exchange ratio determined on the closing of the deal.